Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
manufacturer submits an MF registration<br />
application, it is necessary to appo<strong>in</strong>t a drug<br />
substance manager to h<strong>and</strong>le the activities of<br />
the MF registrant <strong>in</strong> <strong>Japan</strong>.<br />
When the registered contents of the MF<br />
are changed, an application to change the<br />
MF or a slight MF modification notification<br />
must be submitted. However, new<br />
registration applications are required <strong>in</strong> cases<br />
where there is concern that the change <strong>in</strong><br />
registered items will alter the basic nature of<br />
registered items.<br />
When an application to change of the MF<br />
is submitted, the market<strong>in</strong>g authorization<br />
holder must submit a partial change<br />
application or a slight modification notification<br />
for the MF depend<strong>in</strong>g on the contents of the<br />
change. However, when a change or<br />
changes are slight, the market<strong>in</strong>g<br />
authorization holder is not required to submit<br />
a partial change application or a slight<br />
modification notification of approved items.<br />
In both cases, MF registrants must notify the<br />
market<strong>in</strong>g authorization holder or the<br />
manufactur<strong>in</strong>g approval holder of the<br />
change(s).<br />
When approval applications are filed us<strong>in</strong>g<br />
MF registration, a copy of the registration<br />
certificate <strong>and</strong> a copy of the contract with the<br />
registrant related to MF utilization are<br />
required. When <strong>in</strong>quiries concern<strong>in</strong>g MF<br />
registration arise <strong>in</strong> the course of the review,<br />
<strong>in</strong>quiries directly from the PMDA are made to<br />
<strong>Pharmaceutical</strong> <strong>Regulations</strong> <strong>in</strong> <strong>Japan</strong>:<br />
the registrant or the drug substance<br />
manager. When changes are made <strong>in</strong> the<br />
registered contents as a result of the review,<br />
the MF registrant must submit an application<br />
for a change <strong>in</strong> registered content or a slight<br />
modification notification without delay.<br />
3.7 Accreditation of Overseas<br />
Manufacturers<br />
Persons wish<strong>in</strong>g to manufacture drugs,<br />
quasi-drugs, cosmetics, or medical devices<br />
exported to <strong>Japan</strong> from overseas (overseas<br />
manufacturers) must receive accreditation<br />
from the M<strong>in</strong>ister (enforced from April 1,<br />
2005).<br />
The specifications for accreditation are the<br />
same as those for manufactur<strong>in</strong>g licenses for<br />
domestic manufacturers.<br />
The follow<strong>in</strong>g items are taken from the<br />
“Q&A on Accreditation of Overseas<br />
Manufacturers” <strong>in</strong> an office communication of<br />
the Evaluation <strong>and</strong> Licens<strong>in</strong>g Division, PFSB<br />
dated February 14, 2006. Refer to the<br />
PMDA homepage for reference.<br />
http://www.pmda.go.jp/operations/shon<strong>in</strong>/i<br />
nfo/foreign.html (<strong>in</strong> <strong>Japan</strong>ese)<br />
(1) Applicants for accreditation of<br />
overseas manufacturers <strong>and</strong> their<br />
agents<br />
- When the applicant is a corporation,<br />
the representative (director with<br />
representative authority) makes the<br />
2011-3 - 26 -